CU20190069A7 - Compuestos químicos derivados sustituidos de 1h-pirrolo[2,3-b] piridina como moduladores del receptor de hidrocarburos de arilo (ahr) - Google Patents

Compuestos químicos derivados sustituidos de 1h-pirrolo[2,3-b] piridina como moduladores del receptor de hidrocarburos de arilo (ahr)

Info

Publication number
CU20190069A7
CU20190069A7 CU2019000069A CU20190069A CU20190069A7 CU 20190069 A7 CU20190069 A7 CU 20190069A7 CU 2019000069 A CU2019000069 A CU 2019000069A CU 20190069 A CU20190069 A CU 20190069A CU 20190069 A7 CU20190069 A7 CU 20190069A7
Authority
CU
Cuba
Prior art keywords
ahr
modulators
aryl hydrocarbon
hydrocarbon receptor
pyridine
Prior art date
Application number
CU2019000069A
Other languages
English (en)
Inventor
Michael Albers
Ulrich Deuschle
Thomas Hoffmann
Christoph Steeneck
Original Assignee
Phenex Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenex Pharmaceuticals Ag filed Critical Phenex Pharmaceuticals Ag
Publication of CU20190069A7 publication Critical patent/CU20190069A7/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<p>La presente invención se refiere a compuestos químicos derivados sustituidos de 1H-pirrolo [2,3-b] piridina de acuerdo a la fórmula (I)</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>que pueden actuar como moduladores del receptor de hidrocarburos de arilo (AhR) y, en particular, como antagonistas de AhR. Dichos compuestos son útiles para el tratamiento y/o profilaxis de enfermedades y/o condiciones como el cáncer, a través de la unión de dicho receptor de hidrocarburos de arilo por dichos compuestos.</p>
CU2019000069A 2017-02-01 2018-02-01 Compuestos químicos derivados sustituidos de 1h-pirrolo[2,3-b] piridina como moduladores del receptor de hidrocarburos de arilo (ahr) CU20190069A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17000158 2017-02-01
PCT/EP2018/052542 WO2018141857A1 (en) 2017-02-01 2018-02-01 Aryl hydrocarbon receptor (ahr) modulator compounds

Publications (1)

Publication Number Publication Date
CU20190069A7 true CU20190069A7 (es) 2020-03-04

Family

ID=57960223

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000069A CU20190069A7 (es) 2017-02-01 2018-02-01 Compuestos químicos derivados sustituidos de 1h-pirrolo[2,3-b] piridina como moduladores del receptor de hidrocarburos de arilo (ahr)

Country Status (28)

Country Link
US (1) US10981908B2 (es)
EP (1) EP3577112B1 (es)
JP (1) JP6849823B2 (es)
KR (1) KR102320516B1 (es)
CN (1) CN110248940B (es)
AR (1) AR110789A1 (es)
AU (1) AU2018216957B2 (es)
BR (1) BR112019015716A2 (es)
CA (1) CA3050827C (es)
CL (1) CL2019002108A1 (es)
CO (1) CO2019007881A2 (es)
CR (1) CR20190392A (es)
CU (1) CU20190069A7 (es)
EA (1) EA038318B1 (es)
EC (1) ECSP19055169A (es)
ES (1) ES2858329T3 (es)
IL (1) IL268080B (es)
MX (1) MX2019008994A (es)
MY (1) MY196831A (es)
NI (1) NI201900076A (es)
PE (1) PE20191478A1 (es)
PH (1) PH12019550135A1 (es)
SG (1) SG11201906958TA (es)
TW (1) TWI752155B (es)
UA (1) UA122745C2 (es)
UY (1) UY37589A (es)
WO (1) WO2018141857A1 (es)
ZA (1) ZA201904771B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TWI674260B (zh) * 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
EP4219495A1 (en) 2018-02-06 2023-08-02 Ideaya Biosciences, Inc. Ahr modulators
WO2020021024A1 (en) * 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
JP2022511786A (ja) * 2018-11-30 2022-02-01 セルラリティ インク. 新規芳香族化合物によるナチュラルキラー細胞およびilc3細胞の増殖
US20230108408A1 (en) * 2020-01-23 2023-04-06 Phenex Pharmaceuticals Ag Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
WO2021173082A1 (en) 2020-02-26 2021-09-02 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
US20230234967A1 (en) * 2020-05-28 2023-07-27 Senda Biosciences, Inc. Fused Azole Heterocycles as AHR Antagonists
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂
CN115572282B (zh) * 2021-07-05 2024-07-09 华东理工大学 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002500A1 (en) 1990-07-31 1992-02-20 Teikoku Hormone Mfg. Co., Ltd. 2-phenylindole derivative
ATE264318T1 (de) * 1996-11-19 2004-04-15 Amgen Inc Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2007057329A1 (en) 2005-11-18 2007-05-24 F. Hoffmann-La Roche Ag Azaindole-2-carboxamide derivatives
US8563573B2 (en) * 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
ES2749504T3 (es) 2009-10-13 2020-03-20 Ligand Pharm Inc Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos
US20130338201A1 (en) * 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
EP2496081B1 (en) * 2009-11-02 2020-03-25 Ariagen, Inc. Ite for cancer intervention and eradication
PT2531501E (pt) 2010-02-03 2014-02-17 Takeda Pharmaceutical Inibidores da cinase de regulação do sinal de apoptose 1
US8410117B2 (en) 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
CN103179968B (zh) 2010-07-27 2017-10-03 波士顿大学管理委员会 作为癌症疗法的芳烃受体(AhR)调节剂
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
BR112015008564A2 (pt) 2012-10-17 2017-07-04 Hoffmann La Roche derivados de 6-aminoindol como antagonistas de canal trp
WO2014100620A2 (en) 2012-12-21 2014-06-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TW201835070A (zh) 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物

Also Published As

Publication number Publication date
AU2018216957A1 (en) 2019-08-22
KR102320516B1 (ko) 2021-11-02
CR20190392A (es) 2019-10-21
UA122745C2 (uk) 2020-12-28
EA038318B1 (ru) 2021-08-09
ECSP19055169A (es) 2019-08-30
TWI752155B (zh) 2022-01-11
ZA201904771B (en) 2022-05-25
PE20191478A1 (es) 2019-10-16
US20190389857A1 (en) 2019-12-26
MX2019008994A (es) 2019-12-19
NI201900076A (es) 2020-01-23
KR20190104410A (ko) 2019-09-09
US10981908B2 (en) 2021-04-20
IL268080A (en) 2019-09-26
BR112019015716A2 (pt) 2020-03-24
SG11201906958TA (en) 2019-08-27
JP6849823B2 (ja) 2021-03-31
CA3050827A1 (en) 2018-08-09
EA201991599A1 (ru) 2020-03-10
WO2018141857A1 (en) 2018-08-09
CL2019002108A1 (es) 2019-12-20
NZ755709A (en) 2021-04-30
ES2858329T3 (es) 2021-09-30
EP3577112A1 (en) 2019-12-11
CA3050827C (en) 2021-09-07
IL268080B (en) 2022-03-01
MY196831A (en) 2023-05-03
CN110248940B (zh) 2022-07-01
UY37589A (es) 2018-02-28
PH12019550135A1 (en) 2020-06-01
EP3577112B1 (en) 2020-12-30
CN110248940A (zh) 2019-09-17
JP2020506228A (ja) 2020-02-27
CO2019007881A2 (es) 2019-10-09
TW201831480A (zh) 2018-09-01
AR110789A1 (es) 2019-05-02
AU2018216957B2 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
CU20190069A7 (es) Compuestos químicos derivados sustituidos de 1h-pirrolo[2,3-b] piridina como moduladores del receptor de hidrocarburos de arilo (ahr)
CU20190067A7 (es) Compuestos químicos derivados sustituidos de 1h-pirrolo [3,2-c] piridinas como moduladores del receptor de hidrocarburos de arilo (ahr)
UY37610A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
CL2017003055A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares.
CR20160321A (es) Modulares de tetrahidropiridopirazinas de gpr6
NI201800075A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos.
CL2020001546A1 (es) Compuestos de 4-azaindol.
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
CO2018006164A2 (es) Compuestos útiles como inhibidores de cinasa
CO2017005959A2 (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
BR112017009629A2 (pt) triazolo [4,5-d] pirimidinas como agonistas do receptor canabinoide 2
DOP2016000211A (es) Pirazinas moduladoras de gpr6
PH12016501393A1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
CO2017005118A2 (es) Nuevos compuestos hidrosolubles derivados del bencimidazol, utiles para el tratamiento de la fasciolosis